The new, minimally invasive procedure developed by University at Buffalo researchers utilizes delivery of an antibody that targets and thus blocks the pro-inflammatory protein called tumor necrosis factor-alpha (TNF), specifically in the brain
Share this post
Share on facebook
Share on twitter
Share on linkedin
Share on print
Share on email
